Targeting of repeated sequences unique to a gene results in significant increases in antisense oligonucleotide potency

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Vickers, Timothy A ^a   Freier, Susan M ^a   Bui, Huynh Hoa ^a   Watt, Andrew ^a   Crooke, Stanley T ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GLUCAGON RECEPTOR; RIBONUCLEASE H; STAT3 PROTEIN; TAU PROTEIN; TRANSCRIPTOME;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; BINDING AFFINITY; BOK GENE; COMPARATIVE STUDY; DNA SEQUENCE; EXON; GCGR GENE; GENE; GENE EXPRESSION; GENE SEQUENCE; GENE TARGETING; HELA CELL LINE; HEPG2 CELL LINE; HUMAN; INTRON; MAPT GENE; NUCLEOTIDE REPEAT; NUCLEOTIDE SEQUENCE; OGFR GENE; PROTEIN CLEAVAGE; REAL TIME POLYMERASE CHAIN REACTION; STAT3 GENE; TANDEM REPEAT; BINDING SITE; CELL LINE; GENETICS; METABOLISM; REPORTER GENE; RNA SPLICING;

BINDING SITES; CELL LINE; GENE EXPRESSION; GENES, REPORTER; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RECEPTORS, GLUCAGON; REPETITIVE SEQUENCES, NUCLEIC ACID; RIBONUCLEASE H; RNA SPLICING; TRANSCRIPTOME;

EID: 84908042302     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110615     Document Type: Article

References (42)

1. Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annual Review of Pharmacology and Toxicology 50: 259-293.
2. Crooke ST (1999) Molecular mechanisms of action of antisense drugs. Biochim, Biophys Acta 1489: 30-42.
3. Crouch RJ, Dirksen M-L (1985) Ribonucleases H. In: Linn SM, Roberts RJ, editors. Nucleases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. 211-241.
4. Wu H, Lima WF, Zhang H, Fan A, Sun H, et al. (2004) Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs. Journal of Biological Chemistry 279: 17181-17189.
5. Itaya M, Kondo K (1991) Molecular cloning of a ribonuclease H (RNase HI) gene from an extreme thermophile Thermus thermophilus HB8: a thermostable RNase H can functionally replace the Escherichia coli enzyme in vivo. Nucleic Acids Research 19: 4443-4449.
6. Itaya M, McKelvin D, Chatterjie SK, Crouch RJ (1991) Selective cloning of genes encoding RNase H from Salmonella typhimurium, Saccharomyces cerevisiae and Escherichia coli rnh mutant. Mol Genet 227: 438-445.
7. Kanaya S, Itaya M (1992) Expression, purification, and characterization of a recombinant ribonuclease H from Thermus thermophilus HB8. Journal of Biological Chemistry 267: 10184-10192.
8. Rong YW, Carl PL (1990) On the molecular weight and subunit composition of calf thymus ribonuclease H1. Biochemistry 29: 383-389.
9. Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, et al. (2003) Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents. Journal of Biological Chemistry 278: 7108-7118.
10. Bennett CF, Swayze EE (2010) RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform. Annual Review of Pharmacology and Toxicology 50: 259-293.
11. Seth PP, Jazayeri A, Yu J, Allerson CR, Bhat B, et al. (2012) Structure Activity Relationships of [alpha]-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals. Mol Ther Nucleic Acids 1: e47.
12. Lima WF, Wu H, Crooke ST (2007) The RNAse H Mechanism. In: Crooke ST, editor. Antisense Drug Technology Principles, Strategies, and Applications. 2 ed. Boca Raton, FL: CRC Press. 47-74.
13. Freier SM, Watt AT (2007) Basic principles of antisense drug discovery. In: Crooke ST, editor. Antisense Drug Technology Principles, Strategies, and Applications. 2 ed. Boca Raton, FL: CRC Press. 117-142.
14. Lima WF, Vickers TA, Nichols J, Li C, Crooke ST (2014) Defining the factors that contribute to on-target specificity for antisense oligonucleotides. PLOS One 9: e101752.
15. Vickers TA, Wyatt JR, Freier SM (2000) Effects of RNA secondary structure on cellular antisense activity. Nucleic Acids Research 28: 1340-1347.
16. Hodges D, Crooke ST (1995) Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNA by antisense oligonucleotides. Molecular Pharmacology 48: 905-918.
17. Vickers TA, Crooke ST (2014) Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms. PLOS One: In press.
18. Liang X-h, Vickers TA, Guo S, Crooke ST (2011) Efficient and specific knockdown of small non-coding RNAs in mammalian cells and in mice. Nucleic Acids Research 39 (3): e13.
19. Shen W, Liang X-h, Crooke ST (2014) Phosphorothioate oligonucleotides can displace NEAT1 RNA and form nuclear paraspeckle-like structure. Nucleic Acids Research 42: 8648-8662.
20. Liang X-h, Shen W, Sun H, Prakash TP, Crooke ST (2014) TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells Nucleic Acids Research 42: 7819-7832.
21. Langmead B, Trapnell C, Pop M, Salzberg S (2009) Ultrafast and memoryefficient alignment of short DNA sequences to the human genome. Genome Biology 10: R25.
22. Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, et al. (1997) 2′ - O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. Journal of Biological Chemistry 272: 11994-12000.
23. Seth PP, Siwkowski A, Allerson CR, Vasquez G, Lee S, et al. (2008) Design, Synthesis And Evaluation Of Constrained Methoxyethyl (cMOE) and Constrained Ethyl (cEt) Nucleoside Analogs. Nucleic Acids Symposium Series 52: 553-554.
24. Vickers TA, Zhang H, Graham MJ, Lemonidis KM, Zhao C, et al. (2006) Modification of MyD88 mRNA Splicing and Inhibition of IL-1beta Signaling in Cell Culture and in Mice with a 2′-O-Methoxyethyl-Modified Oligonucleotide. Journal of Immunology 176: 3652-3661.
25. Vickers TA, Sabripour M, Crooke ST (2011) U1 adaptors result in reduction of multiple pre-mRNA species principally by sequestering U1snRNP. Nucleic Acids Research 39: e71.
26. Hashimoto JG, Beadles-Bohling AS, Wiren KM (2004) Comparison of RiboGreen and 18S rRNA quantitation for normalizing real-time RT-PCR expression analysis. BioTechniques 36: 58-60.
27. Lima WF, Wu H, Nichols JG, Manalili SM, Drader JJ, et al. (2003) Human RNase H1 activity is regulated by a unique redox switch formed between adjacent cysteines. Journal of Biological Chemistry 278: 14906-14912.
28. Watts LM, Manchem VP, Leedom TA, Rivard AL, McKay RA, et al. (2005) Reduction of Hepatic and Adipose Tissue Glucocorticoid Receptor Expression With Antisense Oligonucleotides Improves Hyperglycemia and Hyperlipidemia in Diabetic Rodents Without Causing Systemic Glucocorticoid Antagonism. Diabetes 54: 1846-1853.
29. Swayze EE, Bhat B (2007) The Medicinal Chemistry of Oligonucleotides. In: Crooke ST, editor. Antisense Drug Technology Principles, Strategies, and Applications. 2 ed. Boca Raton, FL: CRC Press. 143-162.
30. Hu J, Matsui M, Gagnon KT, Schwartz JC, Gabillet S, et al. (2009) Allelespecific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotech 27: 478-484.
31. Donnelly Christopher J, Zhang P-W, Pham Jacqueline T, Haeusler Aaron R, Mistry Nipun A, et al. (2013) RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention. Neuron 80: 415-428.
32. ∅stergaard ME, Southwell AL, Kordasiewicz H, Watt AT, Skotte NH, et al. (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Research 41: 9634-9650.
33. Schwarz DS, Ding H, Kennington L, Moore JT, Schelter J, et al. (2006) Designing siRNA That Distinguish between Genes That Differ by a Single Nucleotide. PLoS Genet 2: e140.
34. Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, et al. (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488: 111-115.
35. Yu D, Pendergraff H, Liu J, Kordasiewicz HB, Cleveland Don W, et al. (2012) Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression. Cell 150: 895-908.
36. Crooke ST (2001) Antisense Drug Technology. In: Crooke ST, editor. Antisense Drug Technology Principles, Strategies, and Applications. New York: Marcel Dekker, Inc. 1-27.
37. Lützelberger M, Kjems J (2006) Strategies to Identify Potential Therapeutic Target Sites in RNA. In: Erdmann V, Barciszewski J, Brosius J, editors. RNA Towards Medicine: Springer Berlin Heidelberg. 243-259.
38. Chalk AM, Sonnhammer ELL (2002) Computational antisense oligo prediction with a neural network model. Bioinformatics 18: 1567-1575.
39. Far RK-K, Leppert J, Frank K, Sczakiel G (2005) Technical Improvements in the Computational Target Search for Antisense Oligonucleotides Oligonucleotides 15: 223-233.
40. Mathews DH, Burkard ME, Freier SM, Wyatt JR, Turner DH (1999) Predicting oligonucleotide affinity to nucleic acid targets. RNA 5: 1458-1469.
41. Gruber AR, Lorenz R, Bernhart SH, Neubo?ck R, Hofacker IL (2008) The Vienna RNA Websuite. Nucleic Acids Research 36: W70-W74.
42. Sugimoto N, Nakano S-i, Katoh M, Matsumura A, Nakamuta H, et al. (1995) Thermodynamic Parameters To Predict Stability of RNA/DNA Hybrid Duplexes. Biochemistry 34: 11211-11216.